Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression

Rhee Hun Kang, Myoung Jin Choi, Jong Woo Paik, Sang Woo Hahn, Min-Soo Lee

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The 5-HTR2A gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the -1438A/G polymorphism of the 5-HTR2A gene and the response to mirtazapine in a Korean population with major depressive disorder. Mirtazapine was administered for eight weeks to the 101 patients who completed the study, during which we evaluated the clinical outcome using repeated-measures ANCOVA. A main effect of genotype or an effect of genotype-time interactions on the decrease in HAMD score during the eight-week follow-up was not found, which suggests that the 5-HTR2A -1438A/G polymorphism does not affect the clinical outcome to mirtazapine administration. However, significant effects of genotype and allele carriers on the decrease in the sleep score over the eight weeks were found (genotype: F = 4.093, p = 0.017; allele: F = 4.371, p = 0.037), whereas no effect of genotype-time interactions on the decrease in the HAMD score over the eight-week follow-up was found. These observations suggest that the -1438A/G polymorphism affects the sleep improvement but not the sleep pattern over time. A t-test-based evaluation of the effect of the 5-HTR2A -1438A/G polymorphism on the sleep improvement at each time period revealed significant differences in the sleep scores after two weeks of mirtazapine administration. The sleep scores were lower for carriers of the A+ allele than of the A- allele after two weeks of mirtazapine administration (p = 0.041), which means that the -1438GG genotype is associated with less improvement in sleep, and suggests that the effect of mirtazapine on improving the sleep quality differs with the 5-HTR2A -1438A/G poly - morphism within two weeks of mirtazapine treatment. In conclusion, although the -1438A/G polymorphism affects the sleep improvement resulting from the administration of mirtazapine to Korean patients with major depressive disorder, our results do not support the hypothesis that this polymorphism of the 5-HTR2A gene is involved in the therapeutic response to mirtazapine.

Original languageEnglish
Pages (from-to)315-329
Number of pages15
JournalInternational Journal of Psychiatry in Medicine
Volume37
Issue number3
DOIs
Publication statusPublished - 2007 Dec 1

Fingerprint

Receptor, Serotonin, 5-HT2A
Sleep
Depression
Genotype
Genes
Alleles
Major Depressive Disorder
Poly G
mirtazapine
Antidepressive Agents
Therapeutics

Keywords

  • 5-HTR2A promoter polymorphism
  • Major depressive disorder
  • Mirtazapine
  • Treatment response

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. / Kang, Rhee Hun; Choi, Myoung Jin; Paik, Jong Woo; Hahn, Sang Woo; Lee, Min-Soo.

In: International Journal of Psychiatry in Medicine, Vol. 37, No. 3, 01.12.2007, p. 315-329.

Research output: Contribution to journalArticle

Kang, Rhee Hun ; Choi, Myoung Jin ; Paik, Jong Woo ; Hahn, Sang Woo ; Lee, Min-Soo. / Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. In: International Journal of Psychiatry in Medicine. 2007 ; Vol. 37, No. 3. pp. 315-329.
@article{f11b088daa074cfbb85cff17050660f3,
title = "Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression",
abstract = "The 5-HTR2A gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the -1438A/G polymorphism of the 5-HTR2A gene and the response to mirtazapine in a Korean population with major depressive disorder. Mirtazapine was administered for eight weeks to the 101 patients who completed the study, during which we evaluated the clinical outcome using repeated-measures ANCOVA. A main effect of genotype or an effect of genotype-time interactions on the decrease in HAMD score during the eight-week follow-up was not found, which suggests that the 5-HTR2A -1438A/G polymorphism does not affect the clinical outcome to mirtazapine administration. However, significant effects of genotype and allele carriers on the decrease in the sleep score over the eight weeks were found (genotype: F = 4.093, p = 0.017; allele: F = 4.371, p = 0.037), whereas no effect of genotype-time interactions on the decrease in the HAMD score over the eight-week follow-up was found. These observations suggest that the -1438A/G polymorphism affects the sleep improvement but not the sleep pattern over time. A t-test-based evaluation of the effect of the 5-HTR2A -1438A/G polymorphism on the sleep improvement at each time period revealed significant differences in the sleep scores after two weeks of mirtazapine administration. The sleep scores were lower for carriers of the A+ allele than of the A- allele after two weeks of mirtazapine administration (p = 0.041), which means that the -1438GG genotype is associated with less improvement in sleep, and suggests that the effect of mirtazapine on improving the sleep quality differs with the 5-HTR2A -1438A/G poly - morphism within two weeks of mirtazapine treatment. In conclusion, although the -1438A/G polymorphism affects the sleep improvement resulting from the administration of mirtazapine to Korean patients with major depressive disorder, our results do not support the hypothesis that this polymorphism of the 5-HTR2A gene is involved in the therapeutic response to mirtazapine.",
keywords = "5-HTR2A promoter polymorphism, Major depressive disorder, Mirtazapine, Treatment response",
author = "Kang, {Rhee Hun} and Choi, {Myoung Jin} and Paik, {Jong Woo} and Hahn, {Sang Woo} and Min-Soo Lee",
year = "2007",
month = "12",
day = "1",
doi = "10.2190/PM.37.3.h",
language = "English",
volume = "37",
pages = "315--329",
journal = "International Journal of Psychiatry in Medicine",
issn = "0091-2174",
publisher = "Baywood Publishing Co. Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression

AU - Kang, Rhee Hun

AU - Choi, Myoung Jin

AU - Paik, Jong Woo

AU - Hahn, Sang Woo

AU - Lee, Min-Soo

PY - 2007/12/1

Y1 - 2007/12/1

N2 - The 5-HTR2A gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the -1438A/G polymorphism of the 5-HTR2A gene and the response to mirtazapine in a Korean population with major depressive disorder. Mirtazapine was administered for eight weeks to the 101 patients who completed the study, during which we evaluated the clinical outcome using repeated-measures ANCOVA. A main effect of genotype or an effect of genotype-time interactions on the decrease in HAMD score during the eight-week follow-up was not found, which suggests that the 5-HTR2A -1438A/G polymorphism does not affect the clinical outcome to mirtazapine administration. However, significant effects of genotype and allele carriers on the decrease in the sleep score over the eight weeks were found (genotype: F = 4.093, p = 0.017; allele: F = 4.371, p = 0.037), whereas no effect of genotype-time interactions on the decrease in the HAMD score over the eight-week follow-up was found. These observations suggest that the -1438A/G polymorphism affects the sleep improvement but not the sleep pattern over time. A t-test-based evaluation of the effect of the 5-HTR2A -1438A/G polymorphism on the sleep improvement at each time period revealed significant differences in the sleep scores after two weeks of mirtazapine administration. The sleep scores were lower for carriers of the A+ allele than of the A- allele after two weeks of mirtazapine administration (p = 0.041), which means that the -1438GG genotype is associated with less improvement in sleep, and suggests that the effect of mirtazapine on improving the sleep quality differs with the 5-HTR2A -1438A/G poly - morphism within two weeks of mirtazapine treatment. In conclusion, although the -1438A/G polymorphism affects the sleep improvement resulting from the administration of mirtazapine to Korean patients with major depressive disorder, our results do not support the hypothesis that this polymorphism of the 5-HTR2A gene is involved in the therapeutic response to mirtazapine.

AB - The 5-HTR2A gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the -1438A/G polymorphism of the 5-HTR2A gene and the response to mirtazapine in a Korean population with major depressive disorder. Mirtazapine was administered for eight weeks to the 101 patients who completed the study, during which we evaluated the clinical outcome using repeated-measures ANCOVA. A main effect of genotype or an effect of genotype-time interactions on the decrease in HAMD score during the eight-week follow-up was not found, which suggests that the 5-HTR2A -1438A/G polymorphism does not affect the clinical outcome to mirtazapine administration. However, significant effects of genotype and allele carriers on the decrease in the sleep score over the eight weeks were found (genotype: F = 4.093, p = 0.017; allele: F = 4.371, p = 0.037), whereas no effect of genotype-time interactions on the decrease in the HAMD score over the eight-week follow-up was found. These observations suggest that the -1438A/G polymorphism affects the sleep improvement but not the sleep pattern over time. A t-test-based evaluation of the effect of the 5-HTR2A -1438A/G polymorphism on the sleep improvement at each time period revealed significant differences in the sleep scores after two weeks of mirtazapine administration. The sleep scores were lower for carriers of the A+ allele than of the A- allele after two weeks of mirtazapine administration (p = 0.041), which means that the -1438GG genotype is associated with less improvement in sleep, and suggests that the effect of mirtazapine on improving the sleep quality differs with the 5-HTR2A -1438A/G poly - morphism within two weeks of mirtazapine treatment. In conclusion, although the -1438A/G polymorphism affects the sleep improvement resulting from the administration of mirtazapine to Korean patients with major depressive disorder, our results do not support the hypothesis that this polymorphism of the 5-HTR2A gene is involved in the therapeutic response to mirtazapine.

KW - 5-HTR2A promoter polymorphism

KW - Major depressive disorder

KW - Mirtazapine

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=37549038223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549038223&partnerID=8YFLogxK

U2 - 10.2190/PM.37.3.h

DO - 10.2190/PM.37.3.h

M3 - Article

VL - 37

SP - 315

EP - 329

JO - International Journal of Psychiatry in Medicine

JF - International Journal of Psychiatry in Medicine

SN - 0091-2174

IS - 3

ER -